Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2025.03.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Toluquinol modulates and circadian rhythm in lung cancer cells: Implications for circadian medicine.
Chronobiol Int
September 2025
Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Lung cancer remains one of the most fatal cancers, with cigarette smoke (CS) exposure being a major risk factor due to its role in triggering oxidative stress. Disruption of circadian rhythms, increasingly common in modern lifestyles, has also been linked to cancer progression. Targeting both oxidative imbalance and circadian disruption may offer a more effective therapeutic approach.
View Article and Find Full Text PDFBackground: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19.
Methods: Patients admitted with COVID-19 pneumonia to 107 UK hospitals were randomly assigned (1:1) to either usual care alone or usual care plus a single 1 g infusion of sotrovimab, using web-based unstratified randomisation.
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.
Br J Haematol
June 2025
Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio, USA.
Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T-cell (CAR-T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR-T for relapsed/refractory large B-cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time-to-peak creatinine from CAR-T of 9.
View Article and Find Full Text PDFAn ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy.
Transplant Cell Ther
September 2025
Division of Hematology, Ohio State University, Columbus, Ohio. Electronic address:
Background: Transplant associated thrombotic microangiopathy (TA-TMA) confers significant morbidity and mortality in hematopoietic cell transplant recipients. The safety and efficacy of multiple TA-TMA directed therapeutic agents are being tested in ongoing clinical trials. In the absence of approved drugs, several treatments are used off-label.
View Article and Find Full Text PDF